Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door
→ While an FDA ruling on Eisai and Biogen’s Alzheimer’s drug lecanemab is imminent, new Biogen CEO Chris Viehbacher is splitting the role of R&D chief into two jobs. The hunt is on for a head of research, but Priya Singhal will lead development after stepping in as interim head of R&D for Al Sandrock in November 2021. Sandrock, meanwhile, has since taken on a reclamation project as CEO of Voyager Therapeutics. After four years at Vertex, Singhal joined Biogen in 2012, then left to become Zafgen’s head of R&D in 2019. She returned to Biogen less than a year later as SVP, head of global safety and regulatory sciences. John Carroll lends some analysis about Viehbacher’s move.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
